ArticleAmerican journal of translational research2026
Improvement of wound healing after diabetic foot debridement by a novel high ankle block: a randomized controlled trial.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06395961 (Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of ultrasound-guided high ankle block (HAB) on postoperative wound healing and foot perfusion after diabetic foot debridement.
methodsThis prospective, assessor-blinded randomized controlled trial (NCT06395961) enrolled 70 patients with Wagner II-IV diabetic foot ulcers undergoing debridement. Thirty-five patients received HAB with 35 mL of 0.375% ropivacaine, and 35 received general anesthesia (GA). The primary outcome was ulcer area on postoperative day 7, measured using ImageJ boundary delineation. Ulcer area was also assessed on days 1, 7, 14, 28, and 60. Secondary outcomes included: anterior and posterior tibial artery hemodynamics assessed by Doppler ultrasound on days 1, 7, and 14; foot skin temperature measured by infrared thermography on days 2, 4, 6, 8, 10, 12, and 14 (to avoid interference with ultrasound measurement); and visual analog scale (VAS) pain scores, opioid consumption, and adverse events assessed at various time points.
resultsThe HAB group showed significantly higher ulcer healing rates on day 7 (42.2% vs. 29.4%,
conclusionHAB enhances foot perfusion, accelerates early ulcer healing, and provides superior analgesia with fewer complications compared with GA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.